ASP Isotopes Outlines 2026 Commercialization Plans

Exec Highlights Upcoming Isotope Shipments Across Nuclear Medicine, Electronics, and Energy

Apr. 13, 2026 at 2:36pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a polished metal cylinder, a glass beaker, and a stack of silicon wafers arranged elegantly on a clean, monochromatic seamless background, conceptually representing ASP Isotopes' diverse product portfolio and strategic positioning.ASP Isotopes' transition from infrastructure to commercial production positions the company as a critical materials platform serving key industries.Washington Today

ASP Isotopes (NASDAQ:ASPI) outlined plans to begin commercial deliveries from multiple enrichment and production assets in 2026, positioning the company as it transitions from infrastructure buildout to product shipments across nuclear medicine, electronic gases, and helium and LNG, executives said on the company's business update call.

Why it matters

ASP Isotopes is aiming to provide a 'credible Western alternative' to Russian-sourced isotopes like Ytterbium-176, which is a key feedstock for the prostate cancer drug Lutetium-177. The company's expansion into radiopharmaceuticals, semiconductor materials, and natural gas processing highlights its strategy to become a diversified critical materials platform.

The details

Executive Chairman and CEO Paul Mann said ASP Isotopes has built three enrichment facilities in South Africa using its proprietary Aerodynamic Separation Process and Quantum Enrichment technologies. The company expects first commercial shipments of Silicon-28, Ytterbium-176, and Carbon-14 in 2026, with timing dependent on operational milestones and feedstock logistics. Mann highlighted isotope supply constraints as a key driver for ASP Isotopes' nuclear medicine strategy, noting that Ytterbium-176 is typically contracted directly between parties and that the company plans to price at about $20,000 per gram, slightly undercutting Russian suppliers. The company also completed the acquisition of Renergen in January 2026, bolstering its helium and LNG production capabilities.

  • The company expects first commercial shipments of Silicon-28, Ytterbium-176, and Carbon-14 in 2026.
  • ASP Isotopes expects to ship its first Silicon-28 product during the second quarter of 2026.
  • The company anticipates initial commercial shipments of Ytterbium-176 around mid-year or the third quarter of 2026.
  • ASP Isotopes expects initial Carbon-14 commercial shipments around mid-year 2026.
  • The company completed its acquisition of Renergen on Jan. 6, 2026.

The players

Paul Mann

Executive Chairman and CEO of ASP Isotopes.

Heather Kiessling

CFO of ASP Isotopes.

Renergen

A company acquired by ASP Isotopes in January 2026, bolstering its helium and LNG production capabilities.

Novartis

A pharmaceutical company that produces the prostate cancer drug Pluvicto, which uses Ytterbium-176 as a feedstock.

East Coast Nuclear

A company acquired by ASP Isotopes, initially focused on SPECT with PET capability planned for 2027.

Got photos? Submit your photos here. ›

What they’re saying

“We are no longer a development stage company. We are a critical materials platform with revenue potential across all business lines.”

— Paul Mann, Executive Chairman and CEO

“Supply today runs predominantly through Russia. We aim to provide a credible Western alternative at commercial scale.”

— Paul Mann, Executive Chairman and CEO

“The plant works. The contract is signed.”

— Paul Mann, Executive Chairman and CEO

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

ASP Isotopes is transitioning from infrastructure buildout to commercial production, aiming to become a diversified critical materials platform that can provide Western alternatives to Russian-sourced isotopes and natural gas products.